Tracon Pharmaceuticals, Inc. financial data

Symbol
TCON on OTC
Industry
Biological Products, (No Diagnostic Substances)
Location
4350 La Jolla Village Drive, Suite 800, San Diego, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 76.6 % +6.18%
Return On Equity -238 % -177%
Return On Assets 57.3 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 3.41M shares -88.9%
Common Stock, Shares, Outstanding 3.41M shares -87.2%
Entity Public Float 7.6M USD -82%
Common Stock, Value, Issued 3K USD -88.9%
Weighted Average Number of Shares Outstanding, Basic 3.01M shares +88.5%
Weighted Average Number of Shares Outstanding, Diluted 3.01M shares +88.5%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 55K USD -99.4%
Research and Development Expense 7.05M USD -57.1%
General and Administrative Expense 5.46M USD -35.8%
Operating Income (Loss) -7.31M USD +64%
Nonoperating Income (Expense) 12.5M USD
Net Income (Loss) Attributable to Parent 5.2M USD +54.8%
Earnings Per Share, Basic 8.32 USD/shares +76.1%
Earnings Per Share, Diluted 8.32 USD/shares +76.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 6.27M USD +261%
Cash, Cash Equivalents, and Short-term Investments 6.3M USD +232%
Assets, Current 6.51M USD -40.8%
Property, Plant and Equipment, Net 30K USD -31.8%
Operating Lease, Right-of-Use Asset 905K USD -19.4%
Assets 7.4M USD -39.3%
Accounts Payable, Current 2.65M USD
Employee-related Liabilities, Current 416K USD -59.7%
Accrued Liabilities, Current 6.82M USD
Liabilities, Current 9.89M USD -63.5%
Other Liabilities, Noncurrent 598K USD -30.1%
Retained Earnings (Accumulated Deficit) -247M USD +2.06%
Stockholders' Equity Attributable to Parent -3.09M USD +80.4%
Liabilities and Equity 7.4M USD -39.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.54M USD +49.2%
Net Cash Provided by (Used in) Financing Activities 1.87M USD
Net Cash Provided by (Used in) Investing Activities -4M USD 0%
Common Stock, Shares Authorized 60M shares 0%
Common Stock, Shares, Issued 3.41M shares -87.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -673K USD +93.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6.34M USD +238%
Deferred Tax Assets, Valuation Allowance 69.3M USD +2.82%
Deferred Tax Assets, Gross 69.5M USD +2.74%
Operating Lease, Liability 968K USD -17.1%
Payments to Acquire Property, Plant, and Equipment 4K USD 0%
Lessee, Operating Lease, Liability, to be Paid 1.17M USD -21.5%
Property, Plant and Equipment, Gross 243K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Two 349K USD +4.49%
Lessee, Operating Lease, Liability, to be Paid, Year One 334K USD +4.38%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 203K USD -37.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 365K USD +4.59%
Deferred Tax Assets, Operating Loss Carryforwards 50.1M USD -1.33%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 10.6M USD +5.27%
Lessee, Operating Lease, Liability, to be Paid, Year Four 123K USD -66.3%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 4K USD 0%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 1.71M USD -12.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%